Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | MOST: an observational study of myelofibrosis and essential thrombocythemia

Abdulraheem Yacoub • 4 Jun 2021
EHA 2021
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Rare Diseases
MOST

Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, gives an overview of the prospective MOST study (NCT02953704) which is investigating the disease and clinical characteristics of patients with essential thrombocythemia. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Abdulraheem Yacoub

2:06
Parsaclisib plus ruxolitinib in myelofibrosis: a promising strategy for treatment-naive patients
Abdulraheem Yacoub • 26 Aug 2022
2:42
The management of advanced phase MPNs
Abdulraheem Yacoub • 26 Aug 2022
4:15
The latest data on momelotinib for MPNs
Abdulraheem Yacoub • 10 Aug 2021
4:11
Novel therapies and combinations for myelofibrosis patients
Abdulraheem Yacoub • 10 Aug 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals